Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.
about
High levels of anti-inflammatory and pro-resolving lipid mediators lipoxins and resolvins and declining docosahexaenoic acid levels in human milk during the first month of lactationHigh-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosisRole of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosisIdentification of IFRD1 as a modifier gene for cystic fibrosis lung diseaseResolvins and omega three polyunsaturated fatty acids: Clinical implications in inflammatory diseases and cancerKey mechanisms governing resolution of lung inflammationResolution of inflammation in asthmaLipidomic profiling of bioactive lipids by mass spectrometry during microbial infectionsModulation of the Activities of Neuronal Ion Channels by Fatty Acid-Derived Pro-ResolventsDHA- and EPA-derived resolvins, protectins, and maresins in airway inflammationSpecialized pro-resolving mediators: endogenous regulators of infection and inflammationRedox-dependent anti-inflammatory signaling actions of unsaturated fatty acidsAltered cholesterol homeostasis in cultured and in vivo models of cystic fibrosisResolution of acute inflammation in the lungPro-Resolving Lipid Mediators (SPMs) and Their Actions in Regulating miRNA in Novel Resolution Circuits in InflammationResolving inflammation: dual anti-inflammatory and pro-resolution lipid mediatorsATF3 is a novel regulator of mouse neutrophil migrationEndogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus.Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis.Systems approach with inflammatory exudates uncovers novel anti-inflammatory and pro-resolving mediators.Lipoxin A4 and platelet activating factor are involved in E. coli or LPS-induced lung inflammation in CFTR-deficient mice.Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators.Genetic variation and clinical heterogeneity in cystic fibrosisNovel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not?Translation control: a multifaceted regulator of inflammatory responseInflammation and its resolution as determinants of acute coronary syndromes.Effect of allergy and inflammation on eicosanoid gene expression in CFTR deficiency.Resolution of Cochlear Inflammation: Novel Target for Preventing or Ameliorating Drug-, Noise- and Age-related Hearing Loss.Impaired clearance of apoptotic cells in chronic inflammatory diseases: therapeutic implicationsLipoxin A4 stimulates calcium-activated chloride currents and increases airway surface liquid height in normal and cystic fibrosis airway epithelia.SOCS2-induced proteasome-dependent TRAF6 degradation: a common anti-inflammatory pathway for control of innate immune responsesNeutrophil unsaturated fatty acid release by GM-CSF is impaired in cystic fibrosisAbnormal unsaturated fatty acid metabolism in cystic fibrosis: biochemical mechanisms and clinical implications.Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway.Endogenous lipid mediators in the resolution of airway inflammationProtectin D1 is generated in asthma and dampens airway inflammation and hyperresponsivenessNovel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins.Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodelingPhysiological levels of lipoxin A4 inhibit ENaC and restore airway surface liquid height in cystic fibrosis bronchial epitheliumTargeting pro-resolution pathways to combat chronic inflammation in COPD
P2860
Q21245689-25B31C56-C92B-4C37-A097-921EFF936C3DQ24545304-761EC37D-66E7-4AFB-A149-64061665ACBAQ24605366-41215B83-8C1D-4413-BF4C-DFE79C259A72Q24621702-D71D0B3E-F2C9-49BD-8930-033D6CCD0B32Q26741524-EE8DE42C-76B6-4229-A592-395124883BBCQ26749606-12B0E2D1-ACA7-4575-B72E-3B7002E78A06Q26823724-3E638555-510D-40E3-8D51-FAB507592DACQ26825122-63212C18-315A-4968-8F05-759D273C1636Q28069355-0D4685C9-6E74-425C-A5C0-463DD506B74EQ28269550-D6974FAB-2AAE-42C1-9798-CF02A74B7991Q28271331-BA3E33CE-849B-4F18-83F0-253E0EE273B4Q28386488-DC15D779-1256-48C0-A0A8-2D6F9194CE06Q28509055-C1292D35-F1E9-4623-9DD2-FD6152EBEA64Q28652204-E9CE8056-E3D6-4BDD-B950-8C4E4BF64F11Q28716294-EFF0D8B2-D31B-4259-BD85-ED37E274BDD2Q29615694-2D1E160D-B4E3-43A1-8E26-14418412CB6EQ30574792-B442A5C7-E469-40E8-9DB7-96DE28442CA2Q31134484-9C5544B7-AB3F-4385-B811-4BC818E61720Q33298018-289BAAB5-A08B-46CA-8CA3-A8CFB6CBB579Q33384350-3E5D231D-7063-45F7-976A-70EB386567F5Q33414226-AF3E5AA7-5A45-4C43-B80A-C68681A10503Q33437576-BE43046B-9BB0-4457-BBD1-CB5BA88B645AQ33645546-73366B46-F398-49A1-959D-D319C1A447CCQ33683210-4EBB3E02-3AB0-4A73-8076-18F7C86B4A14Q33814325-1469C9AC-E2C1-4C18-AC06-DA3884B85C40Q33834800-CBC0F630-EF74-4E92-A057-1AE2694D3755Q33863162-288983A0-732F-4E2E-925F-0D167F66E7CBQ33882297-1A489CCD-78C5-446F-B046-73FA7A12C8F8Q33984427-87019D35-72FB-464F-83B3-5DA49CD5890EQ34291214-559D01FD-4937-4C7E-9285-A3F163A74EF9Q34302552-C2340B82-2A62-43C5-AC08-79E7E22A308BQ34335733-5D667C7E-F150-428E-9606-6B40C107E78DQ34358489-1E884118-FF66-4990-A08E-DACC1CA5C6E7Q34407602-4752A80E-4A78-4D6D-970A-72F5E937D4BBQ34423359-EA56D07D-881C-4BDF-979A-6E8DF3569F8EQ34423365-02B11BDE-AE72-4BE0-92F3-31C6203CCE46Q34522097-436240FF-C00C-4946-B169-02367AE5736CQ34523903-987DBA1F-3BDC-476A-B292-DC3FA5853DBBQ34582407-0734E77B-6858-40D7-81A7-F148B835EBD1Q34628609-45894386-B9BA-4606-A566-2E428ADF7DFD
P2860
Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.
@en
Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.
@nl
type
label
Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.
@en
Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.
@nl
prefLabel
Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.
@en
Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.
@nl
P2093
P50
P356
P1433
P1476
Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.
@en
P2093
Frank J Accurso
Jasim Uddin
Jeffrey A Whitsett
Kiwon W Park
Leah M Flick
Marsha Wills-Karp
Raquel Keledjian
Sowsan F Atabani
Todd M Greer
P304
P356
10.1038/NI1056
P407
P577
2004-03-21T00:00:00Z